The study, conducted by Prof. Eli Schwartz, founder of the Center for Travel Medicine and Tropical Disease at Sheba Medical Center in Tel Hashomer, looked at some 89 eligible volunteers over the age of 18 who had tested positive for coronavirus, and were living in state-run Covid-19 hotels. After being divided into two groups, 50% received ivermectin, and 50% received a placebo. Each patient was given the drug for three days in a row, an hour before eating.

83% of participants were symptomatic at recruitment. 13.5% of patients had comorbidities of cardiovascular disease, diabetes, chronic respiratory disease, hypertension or cancer. The median age of the patients was 35, ranging from 20 to 71-years-old.

Treatment was discontinued on the third day, and patients were monitored every two days thereafter. By day six, 72% of those treated with ivermectin tested negative for the virus, vs. 50% of those who received the placebo.

Meanwhile, just 13% of ivermectin patients were able to infect others after six days compared to 50% of the placebo group - nearly four times as many.

https://www.medrxiv.org/content/10.1101/2021.05.31.21258081v1

It seems like blocking and banning information is required to keep virus spreading level at required numbers.

As we know from other research - modern vaccines are designed such way that they do almost nothing with delta variant concerning its spreading. They only prevent lot of hard cases requiring hospitalization.